Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service EP ablation cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 42 | 2,317 | 33% |
| 2020 | 39 | 1,859 | 36% |
| 2021 | 43 | 2,297 | 39% |
| 2022 | 52 | 2,326 | 41% |
| 2023 | 51 | 2,572 | 43% |
| 2024 | 61 | 3,055 | 45% |
| 2025 from claims | – | 3,788 3,476–4,008 | 46% |
| 2026 forecast | – | 4,082 3,592–4,711 | 46% |
| 2027 forecast | – | 4,391 3,754–5,233 | 47% |
| 2028 forecast | – | 4,723 3,941–5,784 | 47% |
| 2029 forecast | – | 5,080 4,150–6,371 | 47% |
| 2030 forecast | – | 5,464 4,378–7,002 | 48% |
AF, SVT, and VT catheter ablation. Professional codes (what the surgeon bills): CPT 93656, 93653, 93654; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 32% of the cases CMS names in New Jersey; 37 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 21% inpatient hospital, 79% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 138 | 7,854+9.3%/yr | +9.3%/yr | 3.6 | 0% | 15,300 in 2030+12%/yr |
| Pennsylvania | 131 | 5,803+11%/yr | +11%/yr | 3.5 | 0% | 11,400 in 2030+12%/yr |
| Massachusetts | 73 | 4,222+12%/yr | +12%/yr | 4.0 | 0% | 9,560 in 2030+15%/yr |
| Connecticut | 25 | 921+6%/yr | +6%/yr | 2.3 | 0% | 1,750 in 2030+11%/yr |
| New Hampshire | 11 | 595+16%/yr | +16%/yr | 2.3 | 0% | 1,590 in 2030+18%/yr |
| Maine | 10 | 404+10%/yr | +10%/yr | 2.1 | 0% | 870 in 2030+14%/yr |
| Rhode Island | 8 | 382+4.9%/yr | +4.9%/yr | 3.4 | 0% | 920 in 2030+16%/yr |
| Vermont | 6 | 187+11%/yr | +11%/yr | 1.5 | 0% | 630 in 2030+22%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 86 | 4,680−4.6%/yr | −4.6%/yr | 4.60.9× | 0% | 4,910 in 2030+0.8%/yr |
| LAA occlusion & loop recorders | 90 | 3,940+7.1%/yr | +7.1%/yr | 3.41.0× | 37% | 6,480 in 2030+8.7%/yr |
EP ablation in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with New York
Johnson & Johnson MedTech leads with 42% of company spending on these surgeons in 2025, +12 pts on 2024.
In 2025, 7 companies reported engagement with New Jersey’s surgeons worth $288K in consulting, speaking, meals and travel tied to these products, about $4,724 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 102 clearances and approvals in the category, 5 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.